JAK2 and myeloproliferative disorder: Considering that somatic mutations (JAK2, CALR) that occur in the neoplastic clone may maintain a chronic inflammatory state, prothrombotic status and constitutional symptoms have an increased susceptibility to secondary cancers and autoimmune disorders [51]; previous thrombotic events, age, leukocytosis, and the presence of JAK2V617F are predictive of MPN-associated thrombotic complications [52].